Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
T-cell/histiocyte rich large B cell lymphoma (THRLBCL) is a rare variant of diffuse large B-cell lymphoma (DLBCL), mainly affecting middle-aged men and often not being discovered until an advanced disease stage, with involvement of the spleen, liver and bone marrow occurring at a greater frequency than in DLBCL. It is often difficult to diagnose due to its similarity with other lymphoid diseases such as classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma and has an aggressive clinical course.
Biomarker and diagnostic research for T-cell/histiocyte rich large B cell lymphoma has been reported in the published literature.
12 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 9 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05934448](https://clinicaltrials.gov/study/NCT05934448) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 12:15 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about T-cell/histiocyte rich large B cell lymphoma
Pembro Plus CAR T-cell Therapy in R/R in PMBCL |
PHASE2 |
Jennifer Crombie, MD |
RECRUITING |
[NCT06203652](https://clinicaltrials.gov/study/NCT06203652) | The Pathogenesis and Prognostic Factors of Lymphoma | — | Shanghai Zhongshan Hospital | RECRUITING |
[NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | PHASE2 | Mayo Clinic | RECRUITING |
[NCT07097363](https://clinicaltrials.gov/study/NCT07097363) | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | PHASE2 | University of Washington | RECRUITING |
32 publications have been identified in PubMed for T-cell/histiocyte rich large B cell lymphoma. Research spans Case Report / Case Series (25%), Review / Meta-Analysis (19%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 25% |
Research summaries | 6 | 19% |
Testing and diagnosis research | 4 | 13% |
Disease patterns and progression | 4 | 13% |
New treatment approaches | 4 | 13% |
Laboratory research | 3 | 9% |
Clinical study results | 2 | 6% |
Other research | 1 | 3% |
Karhu A (2026). [PMID: 41974450](https://pubmed.ncbi.nlm.nih.gov/41974450/). *Eur J Haematol*. [Epidemiology / Natural History]
Donzel M (2026). [PMID: 42132044](https://pubmed.ncbi.nlm.nih.gov/42132044/). *Am J Surg Pathol*. [Review / Meta-Analysis]
André A (2026). [PMID: 41952624](https://pubmed.ncbi.nlm.nih.gov/41952624/). *Haematologica*. [Epidemiology / Natural History]
Karpathiou G (2026). [PMID: 40883131](https://pubmed.ncbi.nlm.nih.gov/40883131/). *Pathology*. [Diagnostic / Biomarker]
Choy JP (2026). [PMID: 41436860](https://pubmed.ncbi.nlm.nih.gov/41436860/). *British journal of haematology*. [Review / Meta-Analysis]
Gajzer D (2025). [PMID: 39424719](https://pubmed.ncbi.nlm.nih.gov/39424719/). *Methods in molecular biology (Clifton, N.J.)*. [Diagnostic / Biomarker]
Arega G (2025). [PMID: 40026533](https://pubmed.ncbi.nlm.nih.gov/40026533/). *Case reports in oncological medicine*. [Case Report / Case Series]
Mohammed Saleh MF (2025). [PMID: 41459593](https://pubmed.ncbi.nlm.nih.gov/41459593/). *Leukemia & lymphoma*. [Review / Meta-Analysis]
Rausch T (2025). [PMID: 40670673](https://pubmed.ncbi.nlm.nih.gov/40670673/). *Leukemia*. [Basic Science / Preclinical]
Wautlet A (2025). [PMID: 40081918](https://pubmed.ncbi.nlm.nih.gov/40081918/). *BMJ case reports*. [Case Report / Case Series]